Molecular Characterization and Host Range Analysis of Lytic Bacteriophages Targeting Multidrug-Resistant Pseudomonas aeruginosa from Wastewater in Peru

Authors

DOI:

https://doi.org/10.70099/BJ/2025.02.03.2

Keywords:

Pseudomonas aeruginosa, multidrug resistance, bacteriophage therapy, wastewater microbiology, phage stability, host range, RFLP analysis

Abstract

Multidrug-resistant Pseudomonas aeruginosa (MDR-PA) represents a major global public health problem, limiting therapeutic options and increasing morbidity and mortality. This study reports the isolation, molecular characterization, and stability assessment of lytic bacteriophages active against MDR-PA strains recovered from urban wastewater in Trujillo, Peru. Sixteen clinical MDR-PA isolates were confirmed through phenotypic and biochemical tests, and their resistance to 13 antibiotics was evaluated. Eight lytic bacteriophages were obtained and assessed for viability under different storage temperatures (4°C, −30°C, −80°C), elevated temperatures (37–47°C), pH conditions (3, 7, 9), UV radiation exposure (5–60 s), and host range against all bacterial isolates. Molecular characterization was performed by restriction fragment length polymorphism (RFLP) analysis using EcoRI, BamHI, and HindIII enzymes. Phages F1AO-510 and F1AO-506 exhibited the broadest host ranges, lysing 56.25% and 43.75% of MDR-PA strains, respectively. Most phages retained infectivity for three months at 4°C and remained stable at −80°C, whereas UV exposures longer than 30 seconds markedly reduced viability. RFLP profiles revealed distinct genomic patterns, highlighting their genetic diversity and potential for inclusion in targeted phage cocktails. These findings underscore the therapeutic value of lytic bacteriophages as alternative antimicrobial agents and their applicability in phage-based interventions in regions with a high prevalence of antimicrobial resistance.

References

1. Ikpe F, Williams T, Orok E, Ikpe A. Antimicrobial resistance: use of phage therapy in the management of resistant infections. Mol Biol Rep. 21 de agosto de 2024;51(1):925.

2. Bisso-Andrade A. Resistencia bacteriana y el desarrollo de nuevos antimicrobianos. Revista Sociedad Perú de medicina interna. 2012;25(4):2.

3. Das P, Horton R. Physical activity-time to take it seriously and regularly. Lancet. 24 de septiembre de 2016;388(10051):1254-5.

4. Ranjbar R, Alam M. Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Evid Based Nurs. 27 de julio de 2023;ebnurs-2022-103540.

5. Santamaría Corral G. Terapia con bacteriófagos frente a infecciones causadas por cepas multirresistentes de Pseudomonas aeruginosa [Internet] [http://purl.org/dc/dcmitype/Text]. Universidad Autónoma de Madrid; 2024 [citado 28 de enero de 2025]. p. 1. Disponible en: https://dialnet.unirioja.es/servlet/tesis?codigo=340328

6. Shariati A, Azimi T, Ardebili A, Chirani AS, Bahramian A, Pormohammad A, et al. Insertional inactivation of oprD in carbapenem-resistant Pseudomonas aeruginosa strains isolated from burn patients in Tehran, Iran. New Microbes New Infect. enero de 2018;21:75-80.

7. Remold SK, Brown CK, Farris JE, Hundley TC, Perpich JA, Purdy ME. Differential habitat use and niche partitioning by Pseudomonas species in human homes. Microb Ecol. octubre de 2011;62(3):505-17.

8. Askoura M, Mottawea W, Abujamel T, Taher I. Efflux pump inhibitors (EPIs) as new antimicrobial agents against Pseudomonas aeruginosa. The Libyan journal of medicine. 13 de mayo de 2011;6.

9. Montero MM. Pseudomonas aeruginosa multiresistente: aspectos epidemiológicos, clínicos y terapéuticos [Internet] [http://purl.org/dc/dcmitype/Text]. Universitat Autònoma de Barcelona; 2012 [citado 28 de enero de 2025]. Disponible en: https://dialnet.unirioja.es/servlet/tesis?codigo=76881

10. Breidenstein EBM, de la Fuente-Núñez C, Hancock REW. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. agosto de 2011;19(8):419-26.

11. Santos T, Ledbetter E, Caixeta L, Bicalho M, Bicalho R. Isolation and characterization of two bacteriophages with strong in vitro antimicrobial activity against Pseudomonas aeruginosa isolated from dogs with ocular infections. American journal of veterinary research. 1 de agosto de 2011;72:1079-86.

12. Venter H. Reversing resistance to counter antimicrobial resistance in the World Health Organisation’s critical priority of most dangerous pathogens. Biosci Rep. 30 de abril de 2019;39(4):BSR20180474.

13. Nicolas-Chanoine MH, Mayer N, Guyot K, Dumont E, Pagès JM. Interplay Between Membrane Permeability and Enzymatic Barrier Leads to Antibiotic-Dependent Resistance in Klebsiella Pneumoniae. Front Microbiol. 2018;9:1422.

14. Poole K. Mechanisms of bacterial biocide and antibiotic resistance. J Appl Microbiol. 2002;92 Suppl:55S-64S.

15. Arzanlou M, Chai WC, Venter H. Intrinsic, adaptive and acquired antimicrobial resistance in Gram-negative bacteria. Essays Biochem. 28 de febrero de 2017;61(1):49-59.

16. Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev. julio de 2003;16(3):430-50.

17. Hyman P. Phages for Phage Therapy: Isolation, Characterization, and Host Range Breadth. Pharmaceuticals (Basel). 11 de marzo de 2019;12(1):35.

18. Potera C. Phage renaissance: new hope against antibiotic resistance. Environ Health Perspect. febrero de 2013;121(2):a48-53.

19. Sundar M, G S N, Das DrA, Bhattacharya DrS, Suryan S. Isolation of Host-Specific Bacteriophages from Sewage Against Human Pathogens. Asian Journal of Biotechnology. 1 de abril de 2009;1:163-70.

20. Pimienta E. Tratamiento con bacteriófagos como una alternativa antimicrobiana potencial. Revista CENIC Ciencias Biológicas. 22 de mayo de 2013;44.

21. Gutiérrez D, Martín-Platero AM, Rodríguez A, Martínez-Bueno M, García P, Martínez B. Typing of bacteriophages by randomly amplified polymorphic DNA (RAPD)-PCR to assess genetic diversity. FEMS Microbiol Lett. septiembre de 2011;322(1):90-7.

22. Jo SJ, Kwon J, Kim SG, Lee SJ. The Biotechnological Application of Bacteriophages: What to Do and Where to Go in the Middle of the Post-Antibiotic Era. Microorganisms. septiembre de 2023;11(9):2311.

23. Hatfull GF. Bacteriophage genomics. Current Opinion in Microbiology. 1 de octubre de 2008;11(5):447-53.

24. Reina J, Reina N. [Phage therapy, an alternative to antibiotic therapy?)]. Rev Esp Quimioter. abril de 2018;31(2):101-4.

25. García Salazar IA, Porras Nicho MY. Aislamiento de bacteriófagos de Pseudomonas aeruginosa multidrogo – resistente en aguas de tres ríos de la provincia de Lima-Perú. [citado 28 de enero de 2025]; Disponible en: https://cybertesis.unmsm.edu.pe/item/3a4a6c14-a52e-41d9-9542-a6012f1afc3f

26. Gaviria G, González de S. M, Castaño J. Técnica para aislamiento de bacteriófagos específicos para E.coli DH5á a partir de aguas residuales. Revista MVZ Córdoba. 2012;17(1 (enero-abril)):2852-60.

27. Dini M, Shokoohizadeh L, Jalilian FA, Moradi A, Arabestani MR. Genotyping and characterization of prophage patterns in clinical isolates of Staphylococcus aureus. BMC Res Notes. 21 de octubre de 2019;12(1):669.

28. Mitchell R, Jannasch HW. Processes controlling virus inactivation in seawater. Environ Sci Technol. 1 de octubre de 1969;3(10):941-3.

29. Fortier LC, Moineau S. Phage production and maintenance of stocks, including expected stock lifetimes. Methods Mol Biol. 2009;501:203-19.

30. Wong González A. Purificación y caracterización biológica del bacteriófago uB-19 específico de Bacillus thuringiensis [Internet] [masters]. Universidad Autónoma de Nuevo León; 1994 [citado 28 de enero de 2025]. Disponible en: http://eprints.uanl.mx/325/

31. Choi HJ, Kim MH, Cho MS, Kim BK, Kim JY, Kim C, et al. Improved PCR for identification of Pseudomonas aeruginosa. Appl Microbiol Biotechnol. 1 de abril de 2013;97(8):3643-51.

32. Linzitto O, Arias DO, Cerdá R, Del Curto B, Gatti M, Radman N, et al. Revista de Enfermedades Infecciosas Emergentes (REIE) | Volumen 15. Revista de Enfermedades Infecciosas Emergentes (REIE) [Internet]. 2020 [citado 28 de enero de 2025];15. Disponible en: http://sedici.unlp.edu.ar/handle/10915/132699

33. Ruiz-Garbajosa P, Cantón R. Epidemiology of antibiotic resistance in Pseudomonas aeruginosa. Implications for empiric and definitive therapy. Rev Esp Quimioter. septiembre de 2017;30 Suppl 1:8-12.

34. Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Review of Pharmacoeconomics & Outcomes Research. 1 de agosto de 2010;10(4):441-51.

35. Casellas JM. Resistencia a los antibacterianos en América Latina: consecuencias para la infectología. Rev Panam Salud Publica;30(6),dic 2011 [Internet]. 2011 [citado 28 de enero de 2025]; Disponible en: https://iris.paho.org/handle/10665.2/9428

36. Mattila S, Ruotsalainen P, Jalasvuori M. On-Demand Isolation of Bacteriophages Against Drug-Resistant Bacteria for Personalized Phage Therapy. Front Microbiol [Internet]. 13 de noviembre de 2015 [citado 28 de enero de 2025];6. Disponible en: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2015.01271/full

37. Luciano P, Jonás R. Caracterización de un bacteriófago específico de Escherichia coli aislado de aguas residuales de “La Taboada”. [citado 28 de enero de 2025]; Disponible en: https://cybertesis.unmsm.edu.pe/item/1ca5cd03-45d4-4bfd-aa0c-c5cf0faeff7a

38. Dirckze CD, Lehrbach PR, Lee BTO. Effect of Bacteriophage C5 on Ultraviolet Light Survival in Pseudomonas aeruginosa. Microbiology. 1979;112(2):297-300.

39. Dominick F, Jesús V de. Aislamiento y caracterización de un bacteriófago con actividad lítica para Vibrio fluvialis. [citado 28 de enero de 2025]; Disponible en: https://cybertesis.unmsm.edu.pe/item/f63168ec-4d14-4815-a9cb-07d4da1fcb84

40. Sonea S. Bacterial Viruses, Prophages, and Plasmids, Reconsidered. Annals of the New York Academy of Sciences. 1987;503(1):251-60.

41. Guo Y, Chen P, Lin Z, Wang T. Characterization of Two Pseudomonas aeruginosa Viruses vB_PaeM_SCUT-S1 and vB_PaeM_SCUT-S2. Viruses. abril de 2019;11(4):318.

42. Honorio-Javes CE, Vallenas-Sánchez Y, Bazán Pérez JT, Honorio-Javes CE, Vallenas-Sánchez Y, Bazán Pérez JT. Bacteriophage cocktail as a substitute for antibiotic-type growth promoters in poultry. Scientia Agropecuaria. octubre de 2021;12(4):499-508.

43. De Jonge PA, Nobrega FL, Brouns SJJ, Dutilh BE. Molecular and Evolutionary Determinants of Bacteriophage Host Range. Trends Microbiol. enero de 2019;27(1):51-63.

44. Gordillo Altamirano FL, Barr JJ. Phage Therapy in the Postantibiotic Era. Clin Microbiol Rev. abril de 2019;32(2):e00066-18.

45. Lenski RE. Experimental evolution and the dynamics of adaptation and genome evolution in microbial populations. ISME J. octubre de 2017;11(10):2181-94.

46. Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. mayo de 2019;25(5):730-3.

47. Fernández L, González S, Campelo AB, Martínez B, Rodríguez A, García P. Low-level predation by lytic phage phiIPLA-RODI promotes biofilm formation and triggers the stringent response in Staphylococcus aureus. Sci Rep. 19 de enero de 2017;7(1):40965.

48. Melvin JA, Gaston JR, Phillips SN, Springer MJ, Marshall CW, Shanks RMQ, et al. Pseudomonas aeruginosa Contact-Dependent Growth Inhibition Plays Dual Role in Host-Pathogen Interactions. mSphere [Internet]. 15 de noviembre de 2017 [citado 29 de enero de 2025]; Disponible en: https://journals.asm.org/doi/10.1128/msphere.00336-17

49. Philipson CW, Voegtly LJ, Lueder MR, Long KA, Rice GK, Frey KG, et al. Characterizing Phage Genomes for Therapeutic Applications. Viruses. abril de 2018;10(4):188.

50. Ando H, Lemire S, Pires DP, Lu TK. Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing. cels. 23 de septiembre de 2015;1(3):187-96.

51. Oryan A, Yazdi HS, Alidadi S, Doostmohammadi S. Use of a gyrB PCR-RFLP method to diagnose tuberculosis and identify the causative Mycobacterium sp. in cattle and humans. Comparative Immunology, Microbiology and Infectious Diseases. 1 de marzo de 2022;82:101767.

52. Mérault N, Rusniok C, Jarraud S, Gomez-Valero L, Cazalet C, Marin M, et al. Specific Real-Time PCR for Simultaneous Detection and Identification of Legionella pneumophila Serogroup 1 in Water and Clinical Samples. Applied and Environmental Microbiology [Internet]. 1 de marzo de 2011 [citado 29 de enero de 2025]; Disponible en: https://journals.asm.org/doi/10.1128/AEM.02261-10

53. Deschaght P, Van Simaey L, Decat E, Van Mechelen E, Brisse S, Vaneechoutte M. Rapid genotyping of Achromobacter xylosoxidans, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolates using melting curve analysis of RAPD-generated DNA fragments (McRAPD). Research in Microbiology. 1 de mayo de 2011;162(4):386-92.

54. Slauch J, Taylor R, Maloy S. Survival in a cruel world: how Vibrio cholerae and Salmonella respond to an unwilling host. Genes Dev. 15 de julio de 1997;11(14):1761-74.

55. Weigel C, Seitz H. Bacteriophage replication modules. FEMS Microbiology Reviews. 1 de mayo de 2006;30(3):321-81.

Downloads

Published

2025-09-15

How to Cite

González Cabeza, J. G., Huayán Radas, J. L., Córdova Paz Soldán, O. M., González Jara , P. S., Vargas Vásquez , F. R., & Leiva Piedra, J. L. (2025). Molecular Characterization and Host Range Analysis of Lytic Bacteriophages Targeting Multidrug-Resistant Pseudomonas aeruginosa from Wastewater in Peru. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences, 2(3), 23. https://doi.org/10.70099/BJ/2025.02.03.2

Issue

Section

Research Articles

Categories